文献速递核素与放射性配体治疗肿瘤 PET/CT放射性药物与辐射防护

基于PET的风险分层预测[225Ac]Ac-PSMA放射性配体治疗的不良事件

PET-based risk stratification for adverse events under [225Ac]Ac-PSMA radioligand therapy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-02-09

结果显示肾脏SUV是肾脏事件的最强预测因子(OR=0.095,P=0.011),基线Hb是3级贫血的最强预测因子(P=0.002)。PET衍生的肾脏SUV和骨肿瘤体积有望用于治疗前风险分层。

要点

  • 肾脏SUV是肾脏事件最强预测因子(OR=0.095,P=0.011),优于TER和基线eGFR。
  • 基线Hb是3级贫血最强预测因子(P=0.002),骨肿瘤体积也相关(P=0.024)。
  • 低肾脏SUV与更短肾脏事件无生存期相关(P=0.001)。

核心结论

  • PET衍生的肾脏SUV和骨肿瘤体积是[225Ac]Ac-PSMA-I&T RLT期间肾脏和血液学不良事件的有前景预测标志物,可能支持治疗前风险分层。

主要发现

  • 治疗期间eGFR(P=0.0018)和Hb(P=0.0002)均下降,8例(31%)发生肾脏事件,10例(38%)发生3级贫血。
  • 肾脏SUV与eGFR和TER均相关(r≥0.413,P≤0.036),提示PET肾脏定量可能反映肾功能。
  • 肾脏SUV是肾脏事件最强预测因子(OR=0.095,P=0.011),优于TER(P=0.165)和基线eGFR(P=0.245);低SUV与更短肾脏事件无生存期相关(P=0.001)。
  • 基线Hb是3级贫血最强预测因子(P=0.002),血小板、白细胞计数、碱性磷酸酶、骨PSMA-TV和LDH也贡献(各P≤0.037);基线Hb也是无贫血生存最强预测因子(P=0.0007;骨TV,P=0.024)。

关键数值与推荐

  • 肾脏事件定义为eGFR下降≥20%(KDIGO CKD工作组建议),贫血按CTCAE v5分级。

临床怎么用

  • 对接受[225Ac]Ac-PSMA-I&T RLT的mCRPC患者,治疗前可考虑通过[18F]F-PSMA-1007 PET/CT量化肾脏SUV和骨肿瘤体积,结合基线Hb进行肾脏和血液学不良事件风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Actinium-225 prostate-specific membrane antigen radioligand therapy ([225Ac]Ac-PSMA RLT) is a promising salvage option for metastatic castration-resistant prostate cancer (mCRPC). This study aimed to identify predictive parameters for renal and hematological adverse events. METHODS: Twenty-six patients undergoing [225Ac]Ac-PSMA-I&T RLT (mean 3 ± 1 cycles) were retrospectively included. All patients received pretherapeutic Fluor-18 ([18F]F)-PSMA-1007 positron emission tomography/computed tomography (PET/CT) to quantify renal standardized uptake values (SUV) through manual segmentation of both kidneys. Total and osseous PSMA-tumor volume (TV) were also calculated. Additionally, Technetium-99m ([99mTc]Tc)-mercaptoacetyltriglycine (MAG3) renal scintigraphy was performed to assess tubular extraction rates (TER). Standard laboratory values were evaluated at baseline, at and between treatment cycles, including estimated glomerular filtration rate (eGFR) and hemoglobin (Hb). Renal events were defined as an eGFR decline ≥ 20% (Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group recommendations), while anemia was classified according to common terminology criteria of adverse events (CTCAE) version 5. RESULTS: Both eGFR (P = 0.0018) and Hb (P = 0.0002) declined during therapy. Eight patients (31%) experienced renal events, and ten subjects (38%) developed grade 3 anemia. Renal SUV on [18F]F-PSMA-1007 PET/CT correlated with both eGFR and TER (r ≥ 0.413, P ≤ 0.036), suggesting that PET-based renal quantification may reflect renal function. SUV emerged as the strongest predictor of renal events (Odds Ratio [OR] = 0.095, P = 0.011) outperforming TER (P = 0.165) and baseline eGFR (P = 0.245). Based on Kaplan Meier analysis, low SUV was also associated with shorter renal event-free survival (P = 0.001). Baseline Hb (P = 0.002) was the strongest predictor of grade 3 anemia, while additional markers (platelets, white blood cell count, alkaline phosphatase, osseous PSMA-TV and lactate dehydrogenase; each P ≤ 0.037) also contributed. In line, baseline Hb emerged as the strongest predictor of anemia-free survival (P = 0.0007; osseous TV, P = 0.024). CONCLUSION: PET-derived renal SUV and osseous tumor volume are promising predictive markers for renal and hematological adverse events during [225Ac]Ac-PSMA-I&T RLT. These findings may support pretherapeutic risk stratification in this vulnerable patient population.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Widjaja L, Siegmund SC, Gildehaus FJ, et al. PET-based risk stratification for adverse events under [225Ac]Ac-PSMA radioligand therapy. Eur J Nucl Med Mol Imaging. 2026. PMID: 41656419. doi:10.1007/s00259-026-07788-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。